Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Axsome Therapeutics Stock Performance
Shares of NASDAQ:AXSM traded down $3.06 during trading on Tuesday, hitting $128.09. The stock had a trading volume of 1,563,787 shares, compared to its average volume of 1,110,158. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $134.18. The stock has a market capitalization of $6.21 billion, a price-to-earnings ratio of -19.62 and a beta of 1.05. The stock has a 50-day simple moving average of $98.47 and a two-hundred day simple moving average of $93.68.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. On average, equities research analysts expect that Axsome Therapeutics, Inc. will post -4.7 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in Axsome Therapeutics by 14.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock worth $19,062,000 after purchasing an additional 27,534 shares during the period. Strategic Financial Concepts LLC purchased a new stake in shares of Axsome Therapeutics in the fourth quarter worth about $2,599,000. PDT Partners LLC acquired a new stake in Axsome Therapeutics during the third quarter worth about $1,052,000. Pallas Capital Advisors LLC purchased a new position in Axsome Therapeutics during the fourth quarter valued at approximately $2,237,000. Finally, Captrust Financial Advisors purchased a new position in Axsome Therapeutics during the third quarter valued at approximately $514,000. Hedge funds and other institutional investors own 81.49% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the company. Mizuho raised their price objective on Axsome Therapeutics from $137.00 to $195.00 and gave the company an "outperform" rating in a research report on Tuesday, February 11th. Bank of America raised their price target on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Cantor Fitzgerald reiterated an "overweight" rating and set a $121.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft started coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $176.00 target price for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $133.00 price target on shares of Axsome Therapeutics in a research report on Monday, February 10th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $147.13.
Get Our Latest Stock Analysis on AXSM
About Axsome Therapeutics
(
Get Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Featured Articles
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
